Veterinary Medicines

CANIGEN DHPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION FOR DOGS

Authorised
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine distemper virus, strain Lederle, Live
Download as PDF

Product identification

Medicine name:
CANIGEN DHPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION FOR DOGS
Canigen DHPPi, süstesuspensiooni lüofilisaat ja lahusti koertele
Active substance:
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine distemper virus, strain Lederle, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine adenovirus 2, strain Manhattan, Live
    4.00
    log10 50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine parainfluenza virus, strain Manhattan, Live
    5.00
    log10 50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine parvovirus, strain Cornell 780916, Live
    5.00
    log10 50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine distemper virus, strain Lederle, Live
    3.00
    log10 50% tissue culture infectious dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Estonia
Package description:
  • Cardboard box of 1 vial lyophilisate and 1 vial solvent
  • Plastic box of 100 vials lyophilisate and 100 vials solvent
  • Plastic box of 50 vials lyophilisate and 50 vials solvent
  • Plastic box of 25 vials lyophilisate and 25 vials solvent
  • Plastic box of 10 vials lyophilisate and 10 vials solvent
  • Plastic box of 5 vials lyophilisate and 5 vials solvent
  • Plastic box of 1 vial lyophilisate and 1 vial solvent
  • Cardboard box of 100 vials lyophilisate and 100 vials solvent
  • Cardboard box of 50 vials lyophilisate and 50 vials solvent
  • Cardboard box of 25 vials lyophilisate and 25 vials solvent
  • Cardboard boxof 10 vials lyophilisate and 10 vials solvent
  • Cardboard box of 5 vials lyophilisate and 5 vials solvent

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • State Agency Of Medicines
Authorisation number:
  • 1975
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0297/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Estonian (PDF)
Published on: 26/11/2025
Download